RS59159B1 - Cd47 antitela i postupci za njihovu upotrebu - Google Patents

Cd47 antitela i postupci za njihovu upotrebu

Info

Publication number: RS59159B1
Authority: RS; Serbia
Prior art keywords: antibodies; methods
Prior art date: 2012-02-06

Application number

Other languages

English (en)

Inventor

Brendan Eckelman

John Timmer

Amir Razai

Quinn Deveraux

Kyle Jones

Peter L Nguy

Original Assignee

Inhibrx Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-02-06

Filing date

2013-02-06

Publication date

2019-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48947976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS59159(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-02-06 Application filed by Inhibrx Inc filed Critical Inhibrx Inc

2019-10-31 Publication of RS59159B1 publication Critical patent/RS59159B1/sr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

RSP20191071 2012-02-06 2013-02-06 Cd47 antitela i postupci za njihovu upotrebu RS59159B1 (sr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261595216P	2012-02-06	2012-02-06
US201261659752P	2012-06-14	2012-06-14
EP13746964.9A EP2812443B1 (en)	2012-02-06	2013-02-06	Cd47 antibodies and methods of use thereof
PCT/US2013/024995 WO2013119714A1 (en)	2012-02-06	2013-02-06	Cd47 antibodies and methods of use thereof

Publications (1)

Publication Number	Publication Date
RS59159B1 true RS59159B1 (sr)	2019-10-31

Family

ID=48947976

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RSP20191071 RS59159B1 (sr)	2012-02-06	2013-02-06	Cd47 antitela i postupci za njihovu upotrebu

Country Status (36)

Country	Link
US (4)	US9045541B2 (sr)
EP (2)	EP3578569A1 (sr)
JP (1)	JP6273212B2 (sr)
KR (2)	KR102338833B1 (sr)
CN (2)	CN111533804A (sr)
AU (1)	AU2013217114B2 (sr)
BR (1)	BR112014019331A2 (sr)
CA (1)	CA2863834A1 (sr)
CL (1)	CL2014002086A1 (sr)
CO (1)	CO7111273A2 (sr)
CR (1)	CR20140406A (sr)
CY (1)	CY1121911T1 (sr)
DK (1)	DK2812443T3 (sr)
EA (1)	EA034778B1 (sr)
EC (1)	ECSP14016994A (sr)
ES (1)	ES2743203T3 (sr)
HK (1)	HK1205195A1 (sr)
HR (1)	HRP20191500T1 (sr)
HU (1)	HUE13746964T2 (sr)
IL (1)	IL233934B (sr)
LT (1)	LT2812443T (sr)
ME (1)	ME03512B (sr)
MX (1)	MX360772B (sr)
MY (1)	MY169341A (sr)
NZ (1)	NZ628314A (sr)
PE (1)	PE20141908A1 (sr)
PH (1)	PH12014501758B1 (sr)
PL (1)	PL2812443T3 (sr)
PT (1)	PT2812443T (sr)
RS (1)	RS59159B1 (sr)
SG (2)	SG10201700160RA (sr)
SI (1)	SI2812443T1 (sr)
SM (1)	SMT201900453T1 (sr)
UA (1)	UA116772C2 (sr)
WO (1)	WO2013119714A1 (sr)
ZA (1)	ZA201405864B (sr)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2429574E (pt)	2009-05-15	2015-07-17	Univ Health Network	Composições e métodos para o tratamento de cancros hematológicos tendo como alvo a interacção sirp-cd47
CA3027071A1 (en)	2011-01-14	2013-07-19	The Regents Of The University Of California	Therapeutic antibodies against ror-1 protein and methods for use of same
EA034778B1 (ru)	2012-02-06	2020-03-19	Инхибркс, Инк.	Антитела к cd47 и способы их применения
US20140140989A1 (en) *	2012-02-06	2014-05-22	Inhibrx Llc	Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
AU2013353763B2 (en)	2012-12-03	2018-09-13	Novimmune S.A.	Anti-CD47 antibodies and methods of use thereof
US9221908B2 (en)	2012-12-12	2015-12-29	Vasculox, Inc.	Therapeutic CD47 antibodies
CA2894439A1 (en) *	2012-12-12	2014-06-19	Vasculox Inc.	Therapeutic cd47 antibodies
SMT201900623T1 (it)	2012-12-17	2020-01-14	Trillium Therapeutics Inc	Trattamento di cellule di malattia cd47+ con fusioni sirp alpha-fc
EP2953643B1 (en) *	2013-02-06	2023-02-22	Inhibrx, Inc.	Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
EP2970493B1 (en) *	2013-03-15	2019-04-03	The Board of Trustees of the Leland Stanford Junior University	Methods for achieving therapeutically effective doses of anti-cd47 agents
DK3083683T3 (da) *	2013-12-17	2021-01-25	Mhs Care Innovation Llc	Sammensætninger og fremgangsmåder til behandling af fedtvævsansamlinger
US11066467B2 (en)	2013-12-17	2021-07-20	Mhs Care-Innovation Llc	Compositions and methods for treating ischemic heart disease
EP3553087B1 (en) *	2014-01-08	2025-01-01	The Board of Trustees of the Leland Stanford Junior University	Targeted therapy for lung cancer
EP3221358B1 (en)	2014-11-18	2021-07-21	Janssen Pharmaceutica, N.V.	Cd47 antibodies, methods, and uses
WO2016109415A1 (en)	2014-12-30	2016-07-07	Celgene Corporation	Anti-cd47 antibodies and uses thereof
ES2901501T3 (es)	2015-01-21	2022-03-22	Univ Leland Stanford Junior	Uso de agonistas de TLR y agente anti-CD47 para mejorar la fagocitosis de las células cancerosas
MA41463A (fr) *	2015-02-03	2017-12-12	Anaptysbio Inc	Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
US20170151281A1 (en)	2015-02-19	2017-06-01	Batu Biologics, Inc.	Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
TWI778518B (zh) *	2015-03-04	2022-09-21	美商索倫多醫療公司	結合cd47之抗體治療劑
CN104804093A (zh) *	2015-05-27	2015-07-29	江苏春申堂药业有限公司	一种针对cd47的单域抗体
AU2016324316B2 (en)	2015-09-18	2023-02-09	Arch Oncology, Inc.	Therapeutic CD47 antibodies
US9650441B2 (en) *	2015-09-21	2017-05-16	Erasmus University Medical Center	Anti-CD47 antibodies and methods of use
KR20220163516A (ko)	2016-01-11	2022-12-09	포티 세븐, 인코포레이티드	인간화된, 마우스 또는 키메라 항-cd47 단클론 항체
CN115350276A (zh)	2016-04-15	2022-11-18	小利兰·斯坦福大学托管委员会	用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法
US20200255515A1 (en) *	2016-05-09	2020-08-13	Celgene Corporation	Cd47 antibodies and methods of use thereof
CN106084052B (zh) *	2016-06-17	2019-12-27	长春金赛药业股份有限公司	抗cd47单克隆抗体及其应用
CN106117354B (zh) *	2016-06-24	2020-01-14	安徽未名细胞治疗有限公司	一种全人源抗CD47的全分子IgG抗体及其应用
CN109689684B (zh) *	2016-07-06	2022-09-23	细胞基因公司	具有低免疫原性的抗体及其用途
WO2018014068A1 (en) *	2016-07-19	2018-01-25	Teva Pharmaceuticals Australia Pty Ltd	Attenuated type i ifn cd47 combination therapy
EP3487522A4 (en)	2016-07-19	2020-04-01	Teva Pharmaceuticals Australia Pty Ltd	Anti-cd47 combination therapy
CN107955071B (zh) *	2016-10-18	2021-03-26	上海赛远生物科技有限公司	人源抗人cd47抗体及其编码基因与应用
AU2017332960B2 (en) *	2016-10-20	2019-09-12	I-Mab Biopharma Us Limited	Novel CD47 monoclonal antibodies and uses thereof
WO2018075960A1 (en) *	2016-10-21	2018-04-26	Tioma Therapeutics, Inc.	Therapeutic cd47 antibodies
WO2018081448A1 (en)	2016-10-26	2018-05-03	The Board Of Trustees Of The Leland Stanford Junior University	Modified immunoglobulin hinge regions to reduce hemagglutination
WO2018081897A1 (en) *	2016-11-03	2018-05-11	Trillium Therapeutics Inc.	Enhancement of cd47 blockade therapy by proteasome inhibitors
CA3042583A1 (en)	2016-11-03	2018-05-11	Trillium Therapeutics Inc.	Improvements in cd47 blockade therapy by hdac inhibitors
CN108779179B (zh) *	2016-11-28	2022-02-08	江苏恒瑞医药股份有限公司	Cd47抗体、其抗原结合片段及其医药用途
CA3051512A1 (en) *	2017-01-26	2018-08-02	Zlip Holding Limited	Cd47 antigen binding unit and uses thereof
CN111148535A (zh) *	2017-03-22	2020-05-12	安驰肿瘤公司	治疗实体癌和血液癌的组合疗法
AU2018250641B2 (en)	2017-04-11	2025-03-13	Inhibrx Biosciences, Inc.	Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
WO2018189382A1 (en)	2017-04-14	2018-10-18	Solstice Biologics, Ltd.	Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
US20190062428A1 (en)	2017-06-19	2019-02-28	Surface Oncology, Inc.	Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
CN109096395B (zh) *	2017-06-20	2022-06-24	华兰生物工程股份有限公司	阻断型cd47纳米抗体及其用途
FI3658141T3 (fi)	2017-07-24	2023-03-02		Patologisten tilojen hoitaminen suoralla tai epäsuoralla siralfa-cd47-vuorovaikutukseen kohdentamisella
NZ761568A (en) *	2017-08-02	2022-11-25	Phanes Therapeutics Inc	Anti-cd47 antibodies and uses thereof
ES2911243T3 (es) *	2017-08-10	2022-05-18	Grifols Diagnostic Solutions Inc	Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano
SG11202001425TA (en)	2017-08-18	2020-03-30	Ultrahuman Four Ltd	Binding agents
CN109422811A (zh)	2017-08-29	2019-03-05	信达生物制药(苏州)有限公司	抗cd47抗体及其用途
EA039662B1 (ru)	2017-10-03	2022-02-24	Закрытое Акционерное Общество "Биокад"	Антитела, специфичные к cd47 и pd-l1
JP2021500926A (ja)	2017-11-01	2021-01-14	ハミングバード・バイオサイエンス・ホールディングス・プライベート・リミテッド	Ｃｄ４７抗原結合分子
US20210095019A1 (en) *	2017-11-10	2021-04-01	I-Mab	Fusion Proteins Containing CD47 Antibodies and Cytokines
TWI831759B (zh)	2017-12-01	2024-02-11	美商思進公司	Cd47抗體及其用於治療癌症之用途
CA3089512A1 (en) *	2018-01-24	2019-08-01	Nanjing Legend Biotech Co., Ltd.	Anti-cd47 antibodies that do not cause significant red blood cell agglutination
CN110144009B (zh) *	2018-02-14	2020-01-21	上海洛启生物医药技术有限公司	Cd47单域抗体及其用途
CN110305212A (zh)	2018-03-27	2019-10-08	信达生物制药(苏州)有限公司	抗cd47抗体及其用途
WO2019200357A1 (en)	2018-04-12	2019-10-17	Surface Oncology, Inc.	Biomarker for cd47 targeting therapeutics and uses therefor
CN110526972A (zh) *	2018-05-25	2019-12-03	江苏恒瑞医药股份有限公司	一种抗cd47抗体在制备治疗淋巴瘤的药物中的用途
CN110577597B (zh) *	2018-06-11	2021-10-22	康诺亚生物医药科技（成都）有限公司	一种阻断CD47和SIRPα相互作用的抗体
US11634490B2 (en)	2018-06-15	2023-04-25	Accurus Biosciences, Inc.	Blocking antibodies against CD47 and methods of use thereof
CN110615841B (zh) *	2018-06-20	2022-01-04	瑞阳(苏州)生物科技有限公司	抗人cd47单克隆抗体及其应用
CA3104664A1 (en) *	2018-06-29	2020-01-02	North Carolina State University	In situ sprayed bioresponsive immunotherapeutic gel for post-surgical treatment
EP3817769A4 (en) *	2018-07-05	2022-03-30	Trican Biotechnology Co., Ltd	Human anti-cd47 antibodies and uses thereof
CA3110620C (en) *	2018-08-31	2023-06-27	Nanjing Sanhome Pharmaceutical Co., Ltd.	Anti-cd47 antibody and application thereof
CA3107369A1 (en) *	2018-10-31	2020-05-07	I-Mab Biopharma Us Limited	Novel cd47 antibodies and methods of using same
EP3876977A1 (en)	2018-11-06	2021-09-15	The Regents Of The University Of California	Chimeric antigen receptors for phagocytosis
CN111253488A (zh) *	2018-12-03	2020-06-09	上海开拓者生物医药有限公司	Cd47抗体及其制备方法和应用
TW202104260A (zh)	2019-04-05	2021-02-01	美商西建公司	腫瘤選擇性結合ｃｄ４７之抗體之工程
US11013764B2 (en)	2019-04-30	2021-05-25	Myeloid Therapeutics, Inc.	Engineered phagocytic receptor compositions and methods of use thereof
CN110066336B (zh) *	2019-05-12	2021-11-09	杭州科兴生物科技有限公司	抗cd47单克隆抗体、片段及其医药用途
CN114206912B (zh)	2019-06-07	2025-02-11	Alx肿瘤生物技术公司	用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂
AU2020296785A1 (en) *	2019-06-19	2022-01-20	Lepu Biopharma Co., Ltd.	Anti-CD47 antibodies and uses thereof
JP7454645B2 (ja)	2019-07-16	2024-03-22	ギリアードサイエンシーズ，インコーポレイテッド	Ｈｉｖワクチン並びにその作製方法及び使用方法
CN110256565B (zh) *	2019-08-02	2021-03-23	天津大学	抗cd47纳米抗体突变体及其应用
CA3149897A1 (en)	2019-09-03	2021-03-11	Daniel Getts	Methods and compositions for genomic integration
KR20220113353A (ko)	2019-09-18	2022-08-12	람캅 바이오 알파 에이지	Ceacam5 및 cd3에 대한 이중특이적 항체
CA3156160A1 (en) *	2019-09-27	2021-04-01	Beijing Starmab Biomed Technology Ltd.	Monospecific and multi-specific antibodies
JP7371243B2 (ja)	2019-10-18	2023-10-30	フォーティセブン，インコーポレイテッド	骨髄異形成症候群及び急性骨髄性白血病を治療するための併用療法
CN114599681B (zh) *	2019-10-25	2024-01-09	上海药明生物技术有限公司	新型抗cd47抗体及其用途
MX2022005123A (es)	2019-10-31	2022-05-30	Forty Seven Inc	Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico.
US10980836B1 (en)	2019-12-11	2021-04-20	Myeloid Therapeutics, Inc.	Therapeutic cell compositions and methods of manufacturing and use thereof
GB201918230D0 (en)	2019-12-11	2020-01-22	Prec Therapeutics Ltd	Antibodies and their uses
AU2020412875A1 (en)	2019-12-24	2022-06-23	Carna Biosciences, Inc.	Diacylglycerol kinase modulating compounds
US11692038B2 (en)	2020-02-14	2023-07-04	Gilead Sciences, Inc.	Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
WO2021174091A1 (en)	2020-02-28	2021-09-02	Tallac Therapeutics, Inc.	Transglutaminase-mediated conjugation
US20230090014A1 (en)	2020-02-28	2023-03-23	Nanjing Sanhome Pharmaceutical Co., Ltd.	Anti-cd47/anti-pd-l1 antibody and applications thereof
US12091681B2 (en)	2020-03-27	2024-09-17	Mendus B.V.	Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
EP4190813A4 (en) *	2020-07-31	2025-02-12	Bio Thera Solutions Ltd	ANTIBODIES AGAINST CD47 AND ITS APPLICATION
KR20230083300A (ko)	2020-10-07	2023-06-09	셀진 코포레이션	림프계 악성 신생물 병태의 이중특이성 항체 치료
WO2022090556A1 (en)	2020-11-02	2022-05-05	Hummingbird Bioscience Pte. Ltd.	Bcma/taci antigen-binding molecules
IL302639A (en)	2020-11-04	2023-07-01	Myeloid Therapeutics Inc	Engineered chimeric fusion protein compositions and methods of use thereof
US20220196651A1 (en)	2020-12-06	2022-06-23	ALX Oncology Inc.	Multimers for reducing the interference of drugs that bind cd47 in serological assays
KR102757518B1 (ko)	2020-12-07	2025-01-21	(주)이노베이션바이오	Cd47에 특이적인 항체 및 이의 용도
EP4262828A1 (en)	2020-12-18	2023-10-25	Instil Bio (Uk) Limited	Tumor infiltrating lymphocytes and anti-cd47 therapeutics
EP4274853A4 (en) *	2021-01-05	2024-12-04	National Institute Of Biological Sciences, Beijing	BISPECIFIC ANTIBODY TARGETING GPC3 AND CD47
EP4304633A1 (en)	2021-03-12	2024-01-17	Mendus B.V.	Methods of vaccination and use of cd47 blockade
JP2024512004A (ja)	2021-03-17	2024-03-18	マイエロイド・セラピューティクス，インコーポレーテッド	操作されたキメラ融合タンパク質組成物およびその使用方法
TW202302145A (zh)	2021-04-14	2023-01-16	美商基利科學股份有限公司	ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
US11999733B2 (en)	2021-06-23	2024-06-04	Gilead Sciences, Inc.	Diacylglycerol kinase modulating compounds
CA3220923A1 (en)	2021-06-23	2022-12-29	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
US11926628B2 (en)	2021-06-23	2024-03-12	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
EP4359415A1 (en)	2021-06-23	2024-05-01	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
WO2023277281A1 (ko)	2021-06-30	2023-01-05	(주)이노베이션바이오	Cd47에 특이적인 인간화 항체 및 이를 포함하는 cd47 관련 질환의 예방 또는 치료용 약학적 조성물
KR20240091056A (ko)	2021-10-28	2024-06-21	길리애드 사이언시즈, 인코포레이티드	피리디진-3(2h)-온 유도체
CN118201941A (zh)	2021-10-29	2024-06-14	吉利德科学公司	Cd73化合物
CN118488948A (zh)	2021-12-22	2024-08-13	吉利德科学公司	Ikaros锌指家族降解剂及其用途
CN118488946A (zh)	2021-12-22	2024-08-13	吉利德科学公司	Ikaros锌指家族降解剂及其用途
TW202340168A (zh)	2022-01-28	2023-10-16	美商基利科學股份有限公司	Ｐａｒｐ７抑制劑
EP4479084A1 (en)	2022-02-14	2024-12-25	Sana Biotechnology, Inc.	Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
US20230373950A1 (en)	2022-03-17	2023-11-23	Gilead Sciences, Inc.	Ikaros zinc finger family degraders and uses thereof
WO2023183313A1 (en)	2022-03-22	2023-09-28	Sana Biotechnology, Inc.	Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
WO2023183817A1 (en)	2022-03-24	2023-09-28	Gilead Sciences, Inc.	Combination therapy for treating trop-2 expressing cancers
WO2023196784A1 (en)	2022-04-05	2023-10-12	Gilead Sciences, Inc.	Combinations of antibody therapies for treating colorectal cancer
AU2023256670A1 (en)	2022-04-21	2024-10-17	Gilead Sciences, Inc.	Kras g12d modulating compounds
WO2024006929A1 (en)	2022-07-01	2024-01-04	Gilead Sciences, Inc.	Cd73 compounds
WO2024015741A1 (en)	2022-07-12	2024-01-18	Gilead Sciences, Inc.	Hiv immunogenic polypeptides and vaccines and uses thereof
US20240091351A1 (en)	2022-09-21	2024-03-21	Gilead Sciences, Inc.	FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024124107A2 (en)	2022-12-09	2024-06-13	Pfizer Inc.	Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy
WO2024121777A1 (en)	2022-12-09	2024-06-13	Pfizer Inc.	Cd47 blocking agent and anti-bcma / anti-cd3 bispecific antibody combination therapy
CN118221812A (zh) *	2022-12-14	2024-06-21	上海迈石生物技术有限公司	一种靶向cd47的单克隆抗体及其应用
WO2024137852A1 (en)	2022-12-22	2024-06-27	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
WO2024177978A1 (en) *	2023-02-24	2024-08-29	The Regents Of The University Of California	Lilrb3 engager cells
WO2024215754A1 (en)	2023-04-11	2024-10-17	Gilead Sciences, Inc.	Kras modulating compounds
WO2024220917A1 (en)	2023-04-21	2024-10-24	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
US20250042922A1 (en)	2023-06-30	2025-02-06	Gilead Sciences, Inc.	Kras modulating compounds
US20250066328A1 (en)	2023-07-26	2025-02-27	Gilead Sciences, Inc.	Parp7 inhibitors
WO2025024811A1 (en)	2023-07-26	2025-01-30	Gilead Sciences, Inc.	Parp7 inhibitors
WO2025054347A1 (en)	2023-09-08	2025-03-13	Gilead Sciences, Inc.	Kras g12d modulating compounds
WO2025054530A1 (en)	2023-09-08	2025-03-13	Gilead Sciences, Inc.	Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
CN117004700A (zh) *	2023-10-07	2023-11-07	北京爱博生生物技术有限公司	单克隆抗体可变区基因高通量测序的方法及其所用组合物与试剂盒

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
FR2413974A1 (fr)	1978-01-06	1979-08-03	David Bernard	Sechoir pour feuilles imprimees par serigraphie
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
US4681581A (en)	1983-12-05	1987-07-21	Coates Fredrica V	Adjustable size diaper and folding method therefor
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5776093A (en)	1985-07-05	1998-07-07	Immunomedics, Inc.	Method for imaging and treating organs and tissues
US4735210A (en)	1985-07-05	1988-04-05	Immunomedics, Inc.	Lymphographic and organ imaging method and kit
US5101827A (en)	1985-07-05	1992-04-07	Immunomedics, Inc.	Lymphographic and organ imaging method and kit
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US5030719A (en)	1986-08-28	1991-07-09	Teijin Limited	Cytotoxic antibody conjugates and a process for preparation thereof
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5648471A (en)	1987-12-03	1997-07-15	Centocor, Inc.	One vial method for labeling antibodies with Technetium-99m
US5057604A (en)	1988-08-03	1991-10-15	Washington University	Novel monoclonal antibodies
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
CA2062795A1 (en)	1989-06-29	1990-12-30	Michael W. Fanger	Bispecific reagents for aids therapy
EP0486622B1 (en)	1989-08-09	1998-11-04	Rhomed, Incorporated	Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5013556A (en)	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
WO1991010741A1 (en)	1990-01-12	1991-07-25	Cell Genesys, Inc.	Generation of xenogeneic antibodies
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5151510A (en)	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en)	1990-08-29	1999-02-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en)	1991-12-17	1993-06-24	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en)	1990-08-29	2001-10-09	Genpharm International	Transgenic non-human animals for producing heterologous antibodies
ATE352612T1 (de)	1990-08-29	2007-02-15	Pharming Intellectual Pty Bv	Homologe rekombination in säugetier-zellen
US6255458B1 (en)	1990-08-29	2001-07-03	Genpharm International	High affinity human antibodies and human antibodies against digoxin
EP0814159B1 (en)	1990-08-29	2005-07-27	GenPharm International, Inc.	Transgenic mice capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5194594A (en)	1990-09-07	1993-03-16	Techniclone, Inc.	Modified antibodies
WO1992020373A1 (en)	1991-05-14	1992-11-26	Repligen Corporation	Heteroconjugate antibodies for treatment of hiv infection
WO1992022670A1 (en)	1991-06-12	1992-12-23	Genpharm International, Inc.	Early detection of transgenic embryos
WO1992022645A1 (en)	1991-06-14	1992-12-23	Genpharm International, Inc.	Transgenic immunodeficient non-human animals
WO1993004169A1 (en)	1991-08-20	1993-03-04	Genpharm International, Inc.	Gene targeting in animal cells using isogenic dna constructs
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
DE69233782D1 (de)	1991-12-02	2010-05-20	Medical Res Council	Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5777085A (en)	1991-12-20	1998-07-07	Protein Design Labs, Inc.	Humanized antibodies reactive with GPIIB/IIIA
EP0592677B1 (en)	1992-02-18	2001-11-07	Otsuka Kagaku Kabushiki Kaisha	Beta-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF
US5233409A (en)	1992-02-25	1993-08-03	Schwab Karl W	Color analysis of organic constituents in sedimentary rocks for thermal maturity
US5714350A (en)	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
WO1994000569A1 (en)	1992-06-18	1994-01-06	Genpharm International, Inc.	Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
ES2301158T3 (es)	1992-07-24	2008-06-16	Amgen Fremont Inc.	Produccion de anticuerpos xenogenicos.
PT752248E (pt)	1992-11-13	2001-01-31	Idec Pharma Corp	Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
EP0754225A4 (en)	1993-04-26	2001-01-31	Genpharm Int	HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
ATE235549T1 (de)	1993-04-30	2003-04-15	Biognostik Ges	Antisense oligonukleotide zur behandlung von immunsuppressiven wirkungen von tgf-beta2
ATE196313T1 (de)	1993-06-04	2000-09-15	Us Health	Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide
US5625825A (en)	1993-10-21	1997-04-29	Lsi Logic Corporation	Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
EP0745134A1 (en)	1994-02-22	1996-12-04	Danafarber Cancer Institute	Nucleic acid delivery system, method of synthesis and uses thereof
US5643763A (en)	1994-11-04	1997-07-01	Genpharm International, Inc.	Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5703057A (en)	1995-04-07	1997-12-30	Board Of Regents The University Of Texas System	Expression library immunization
CA2219486A1 (en)	1995-04-28	1996-10-31	Abgenix, Inc.	Human antibodies derived from immunized xenomice
CA2230759C (en)	1995-08-29	2012-02-21	Kirin Beer Kabushiki Kaisha	Chimeric animal and method for producing the same
US6025130A (en)	1996-04-04	2000-02-15	Mercator Genetics, Inc.	Hereditary hemochromatosis gene
EP2305027B1 (en)	1996-12-03	2014-07-02	Amgen Fremont Inc.	Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
EP1035132B1 (en) *	1997-09-11	2008-05-14	Chugai Seiyaku Kabushiki Kaisha	Monoclonal antibody inducing apoptosis
EP1167388A4 (en)	1999-03-10	2002-05-29	Chugai Pharmaceutical Co Ltd	APOPTOSE INDUCING SINGLE STRING FV
US6833268B1 (en)	1999-06-10	2004-12-21	Abgenix, Inc.	Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US7282556B2 (en)	2001-05-15	2007-10-16	Emory University	Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47
KR100454414B1 (ko)	2001-06-25	2004-10-26	주식회사 진생사이언스	산소를 이용한 개량 홍삼의 제조 방법
CA2485548A1 (en)	2002-05-10	2004-02-19	Purdue Research Foundation	Epha2 agonistic monoclonal antibodies and methods of use thereof
EP1530418A4 (en)	2002-05-31	2005-10-12	Univ Leland Stanford Junior	METHOD FOR IDENTIFYING AND INSULATING STEM CELLS AND CANCER STAMPS
US8613922B2 (en)	2003-04-24	2013-12-24	The University Of North Carolina At Chapel Hill	Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US20100215640A1 (en)	2003-04-24	2010-08-26	The University Of North Carolina At Chapel Hill	Method for inhibiting cellular activation by insulin-like growth factor-1
US20040213792A1 (en)	2003-04-24	2004-10-28	Clemmons David R.	Method for inhibiting cellular activation by insulin-like growth factor-1
JP4637749B2 (ja)	2003-11-11	2011-02-23	中外製薬株式会社	ヒト化抗ｃｄ４７抗体
JP4970948B2 (ja)	2003-12-05	2012-07-11	ボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティ	癌幹細胞の同定、単離、および除去の方法
ES2397631T3 (es)	2003-12-25	2013-03-08	Kyowa Hakko Kirin Co., Ltd.	Mutante antagonista de anticuerpos ANTI-CD40
WO2005079479A2 (en)	2004-02-17	2005-09-01	Absalus, Inc.	Super-humanized antibodies against respiratory syncytial virus
DK1755660T3 (da)	2004-05-07	2010-07-19	Univ North Carolina	Fremgangsmåde til forbedring eller hæmning af insulin-lignende vækstfaktor-I
US8187595B2 (en)	2004-05-07	2012-05-29	The University Of North Carolina At Chapel Hill	Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
US7728880B2 (en)	2004-06-25	2010-06-01	Qualcomm Incorporated	Automatic white balance method and apparatus
EP2354160A1 (en)	2005-08-31	2011-08-10	Schering Corporation	Engineered anti-IL-23-antibodies
US20090191202A1 (en)	2005-09-29	2009-07-30	Jamieson Catriona Helen M	Methods for manipulating phagocytosis mediated by CD47
US7514229B2 (en)	2005-09-29	2009-04-07	The Board Of Trustees Of The Leland Stanford Junior University	Methods for diagnosing and evaluating treatment of blood disorders
US20080131431A1 (en) *	2006-05-15	2008-06-05	Viral Logic Systems Technology Corp.	CD47 related compositions and methods for treating immunological diseases and disorders
EP2178916B1 (en)	2007-07-31	2014-12-17	Regeneron Pharmaceuticals, Inc.	Human antibodies to human cd20 and method of using thereof
UY31504A1 (es)	2007-11-30	2009-07-17		Construcciones de union de antigenos
CA2965198C (en)	2008-01-15	2021-02-16	The Board Of Trustees Of The Leland Stanford Junior University	Markers of acute myeloid leukemia stem cells
PT3056514T (pt)	2008-01-15	2019-07-19	Univ Leland Stanford Junior	Métodos para manipulação de fagocitose mediada por cd47
KR100962704B1 (ko)	2008-07-02	2010-06-11	유상규	일측 단말의 제어로 타 단말의 주변장치를 이용하는 단말장치 및 그 인터페이스 방법
JP5623401B2 (ja)	2008-08-14	2014-11-12	テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド	抗ｉｌ−１２／ｉｌ−２３抗体
CN102245773B (zh) *	2008-11-03	2014-08-27	阿莱斯亚生物疗法股份有限公司	特异性地阻滞肿瘤抗原的生物活性的抗体
PL2477648T3 (pl) *	2009-09-15	2022-11-07	The Board Of Trustees Of The Leland Stanford Junior University	Synergistyczna terapia anty-cd47 dla nowotworów hematologicznych
US9151760B2 (en)	2009-09-29	2015-10-06	The Board Of Trustees Of The Leland Stanford Junior University	Isolation and use of melanoma cancer stem cells
US20120283124A1 (en)	2009-11-10	2012-11-08	Park Christopher Y	Cell Surface Marker Expression in Hematopoietic Stem Cells and Progenitors for the Diagnosis, Prognosis, and Treatment of Myelodysplastic Syndromes
JP6166177B2 (ja)	2010-05-14	2017-07-19	ザボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティー	Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体
WO2012021867A2 (en)	2010-08-13	2012-02-16	The Johns Hopkins University	A comprehensive methylome map of myeloid and lymphoid commitment from hematopoietic progenitors
WO2012088309A1 (en)	2010-12-21	2012-06-28	The Board Of Trustees Of The Leland Stanford Junior University	Therapeutic and diagnostic methods for manipulating phagocytosis through calreticulin and low density lipoprotein-related receptor
SI2804617T1 (sl)	2012-01-17	2020-10-30	The Board Of Trustees Of The Leland Stanford Junior University	Visokoafinitetni SIRP-alfa reagenti
US20140140989A1 (en) *	2012-02-06	2014-05-22	Inhibrx Llc	Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
EA034778B1 (ru) *	2012-02-06	2020-03-19	Инхибркс, Инк.	Антитела к cd47 и способы их применения
US9073996B2 (en)	2012-08-31	2015-07-07	The University Of North Carolina At Chapel Hill	Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)
EP2953643B1 (en)	2013-02-06	2023-02-22	Inhibrx, Inc.	Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
US9111624B2 (en)	2013-03-22	2015-08-18	Katsuyuki Fujita	Semiconductor memory device

2013
- 2013-02-06 EA EA201400875A patent/EA034778B1/ru not_active IP Right Cessation
- 2013-02-06 PL PL13746964T patent/PL2812443T3/pl unknown
- 2013-02-06 KR KR1020207009892A patent/KR102338833B1/ko active Active
- 2013-02-06 SI SI201331564T patent/SI2812443T1/sl unknown
- 2013-02-06 RS RSP20191071 patent/RS59159B1/sr unknown
- 2013-02-06 MX MX2014009427A patent/MX360772B/es active IP Right Grant
- 2013-02-06 HU HUE13746964A patent/HUE13746964T2/hu unknown
- 2013-02-06 CA CA2863834A patent/CA2863834A1/en active Pending
- 2013-02-06 US US13/761,087 patent/US9045541B2/en active Active
- 2013-02-06 ME MEP-2019-232A patent/ME03512B/me unknown
- 2013-02-06 PT PT13746964T patent/PT2812443T/pt unknown
- 2013-02-06 CN CN202010418862.1A patent/CN111533804A/zh active Pending
- 2013-02-06 DK DK13746964.9T patent/DK2812443T3/da active
- 2013-02-06 JP JP2014556634A patent/JP6273212B2/ja active Active
- 2013-02-06 KR KR1020147025286A patent/KR102100388B1/ko active IP Right Grant
- 2013-02-06 AU AU2013217114A patent/AU2013217114B2/en active Active
- 2013-02-06 EP EP19173042.3A patent/EP3578569A1/en active Pending
- 2013-02-06 LT LTEP13746964.9T patent/LT2812443T/lt unknown
- 2013-02-06 SG SG10201700160RA patent/SG10201700160RA/en unknown
- 2013-02-06 MY MYPI2014002294A patent/MY169341A/en unknown
- 2013-02-06 SM SM20190453T patent/SMT201900453T1/it unknown
- 2013-02-06 EP EP13746964.9A patent/EP2812443B1/en active Active
- 2013-02-06 ES ES13746964T patent/ES2743203T3/es active Active
- 2013-02-06 WO PCT/US2013/024995 patent/WO2013119714A1/en active Application Filing
- 2013-02-06 CN CN201380017900.0A patent/CN104271757B/zh active Active
- 2013-02-06 BR BR112014019331A patent/BR112014019331A2/pt not_active Application Discontinuation
- 2013-02-06 PE PE2014001225A patent/PE20141908A1/es not_active Application Discontinuation
- 2013-02-06 SG SG11201404638SA patent/SG11201404638SA/en unknown
- 2013-02-06 NZ NZ628314A patent/NZ628314A/en unknown
- 2013-06-02 UA UAA201409709A patent/UA116772C2/uk unknown
2014
- 2014-08-04 IL IL233934A patent/IL233934B/en unknown
- 2014-08-05 PH PH12014501758A patent/PH12014501758B1/en unknown
- 2014-08-06 CO CO14171778A patent/CO7111273A2/es unknown
- 2014-08-06 CL CL2014002086A patent/CL2014002086A1/es unknown
- 2014-08-11 ZA ZA2014/05864A patent/ZA201405864B/en unknown
- 2014-09-01 CR CR20140406A patent/CR20140406A/es unknown
- 2014-09-02 EC ECIEPI201416994A patent/ECSP14016994A/es unknown
2015
- 2015-04-29 US US14/700,105 patent/US9663575B2/en active Active
- 2015-06-17 HK HK15105746.9A patent/HK1205195A1/xx unknown
- 2015-08-31 US US14/841,619 patent/US20160251435A1/en not_active Abandoned
2019
- 2019-08-19 CY CY20191100884T patent/CY1121911T1/el unknown
- 2019-08-20 HR HRP20191500 patent/HRP20191500T1/hr unknown
2021
- 2021-02-08 US US17/170,854 patent/US20210317205A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2013217114A1 (en)	2014-09-18
JP2015508072A (ja)	2015-03-16
CL2014002086A1 (es)	2015-02-27
EP2812443A1 (en)	2014-12-17
EP2812443A4 (en)	2015-11-04
US9663575B2 (en)	2017-05-30
CR20140406A (es)	2014-12-10
JP6273212B2 (ja)	2018-01-31
LT2812443T (lt)	2019-09-10
WO2013119714A1 (en)	2013-08-15
CN104271757B (zh)	2020-06-09
MY169341A (en)	2019-03-21
NZ628314A (en)	2017-01-27
ZA201405864B (en)	2015-11-25
DK2812443T3 (da)	2019-08-26
KR20150008049A (ko)	2015-01-21
IL233934A0 (en)	2014-09-30
PE20141908A1 (es)	2014-12-21
ME03512B (me)	2020-04-20
US20210317205A1 (en)	2021-10-14
HRP20191500T1 (hr)	2019-11-29
US20150238604A1 (en)	2015-08-27
PH12014501758B1 (en)	2019-03-06
CA2863834A1 (en)	2013-08-15
SMT201900453T1 (it)	2019-11-13
CY1121911T1 (el)	2020-10-14
PL2812443T3 (pl)	2020-01-31
MX360772B (es)	2018-11-15
AU2013217114B2 (en)	2017-03-30
EA201400875A1 (ru)	2015-01-30
US9045541B2 (en)	2015-06-02
SI2812443T1 (sl)	2019-10-30
HUE13746964T2 (hu)	2020-01-28
EP2812443B1 (en)	2019-05-29
BR112014019331A8 (pt)	2018-01-16
CO7111273A2 (es)	2014-11-10
KR102100388B1 (ko)	2020-04-13
CN104271757A (zh)	2015-01-07
SG11201404638SA (en)	2014-09-26
KR20200040897A (ko)	2020-04-20
PH12014501758A1 (en)	2014-11-10
SG10201700160RA (en)	2017-03-30
EP3578569A1 (en)	2019-12-11
ECSP14016994A (es)	2015-09-30
CN111533804A (zh)	2020-08-14
HK1205195A1 (en)	2015-12-11
US20160251435A1 (en)	2016-09-01
US20130224188A1 (en)	2013-08-29
EA034778B1 (ru)	2020-03-19
IL233934B (en)	2022-04-01
PT2812443T (pt)	2019-09-05
ES2743203T3 (es)	2020-02-18
KR102338833B1 (ko)	2021-12-13
UA116772C2 (uk)	2018-05-10
BR112014019331A2 (pt)	2022-07-12
MX2014009427A (es)	2015-05-11

Publication	Publication Date	Title
HK1205195A1 (en)	2015-12-11	Cd47 antibodies and methods of use thereof cd47
HRP20181457T1 (hr)	2018-11-16	Anti-htra1 protutijela i postupci uporabe
IL263320A (en)	2018-12-31	Anti-hemagglutinin antibodies and methods of use
ZA201501858B (en)	2016-11-30	Anti-mcam antibodies and associated methods of use
PT2925782T (pt)	2020-04-22	Anticorpos anti-cd47 e métodos de utilização destes
HK1205517A1 (en)	2015-12-18	Anti sez6 antibodies and methods of use sez6
IL238227A0 (en)	2015-06-30	Antibodies against c16orf54 and uses thereof
ZA201404675B (en)	2016-11-30	Anti-lrp5 antibodies and methods of use
ZA201403760B (en)	2017-09-27	Anti-cd98 antibodies and methods of use thereof
HK1201843A1 (en)	2015-09-11	Anti-polyubiquitin antibodies and methods of use
HK1208235A1 (en)	2016-02-26	Anti-biotin antibodies and methods of use
HK1209432A1 (en)	2016-04-01	Anti-jagged antibodies and methods of use
HK1203354A1 (en)	2015-10-30	Anti-theophylline antibodies and methods of use